TD Cowen lowered the firm’s price target on DaVita (DVA) to $154 from $157 and keeps a Hold rating on the shares. The firm notes the company beat consensus EBIT but reiterated FY25 guide given lower expected tx and RPT growth. Patient care cost performance and international expected to offset. The continued tepid volume growth is weighing on shares and will likely continue to be the main investor debate, but TD Cowen sees management navigating this and achieving FY25 guidance.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVA: